Unknown

Dataset Information

0

Metabolomic adaptations and correlates of survival to immune checkpoint blockade.

ABSTRACT: Despite remarkable success of immune checkpoint inhibitors, the majority of cancer patients have yet to receive durable benefits. Here, in order to investigate the metabolic alterations in response to immune checkpoint blockade, we comprehensively profile serum metabolites in advanced melanoma and renal cell carcinoma patients treated with nivolumab, an antibody against programmed cell death protein 1 (PD1). We identify serum kynurenine/tryptophan ratio increases as an adaptive resistance mechanism associated with worse overall survival. This advocates for patient stratification and metabolic monitoring in immunotherapy clinical trials including those combining PD1 blockade with indoleamine 2,3-dioxygenase/tryptophan 2,3-dioxygenase   (IDO/TDO) inhibitors.

SUBMITTER: Li H 

PROVIDER: S-EPMC6761178 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Despite remarkable success of immune checkpoint inhibitors, the majority of cancer patients have yet to receive durable benefits. Here, in order to investigate the metabolic alterations in response to immune checkpoint blockade, we comprehensively profile serum metabolites in advanced melanoma and renal cell carcinoma patients treated with nivolumab, an antibody against programmed cell death protein 1 (PD1). We identify serum kynurenine/tryptophan ratio increases as an adaptive resistance mechan  ...[more]

Similar Datasets

Unknown Genomic correlates of response to immune checkpoint blockade.
| S-EPMC6599710 | biostudies-literature
Other IMMUNE CORRELATES OF RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN ACUTE MYELOID LEUKAEMIA
2022-09-16 | GSE178926 | GEO
Unknown Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors.
| S-EPMC6119118 | biostudies-literature
Unknown Immune checkpoint blockade for glioma
| S-EPMC6464918 | biostudies-literature
Unknown Immune checkpoint blockade in infectious diseases.
| S-EPMC5991909 | biostudies-literature
Unknown Immune-Checkpoint Blockade Therapy in Lymphoma.
| S-EPMC7432396 | biostudies-literature
Unknown Immune Checkpoint Blockade for Breast Cancer.
| S-EPMC6061922 | biostudies-literature
Unknown Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.
| S-EPMC5061538 | biostudies-other
Unknown Immune-related Adverse Events after Immune Checkpoint Blockade-based Therapy Are Associated with Improved Survival in Advanced Sarcomas.
| S-EPMC10583739 | biostudies-literature
Unknown Acquired Resistance to Immune Checkpoint Blockade Therapies.
| S-EPMC7280955 | biostudies-literature